Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

Stopped Sufficient evidence of efficacy not met. Discontinuation not based on any safety concerns.

Conditions

• Down Syndrome
• Cognitive Dysfunction

Interventions

• DRUG: Aricept (donepezil hydrochloride)
• DRUG: Aricept (donepezil hydrochloride)
• DRUG: Placebo

Sponsor

Eisai Inc.

Collaborators

• [object Object]